Sa. Skull et al., Should programmes for community-level meningococcal vaccination be considered in Australia? An economic evaluation, INT J EPID, 30(3), 2001, pp. 571-578
Citations number
22
Categorie Soggetti
Envirnomentale Medicine & Public Health","Medical Research General Topics
Background Disease due to serogroup C Neisseria meningitidis is life-threat
ening and potentially preventable by vaccination. In 1999, the UK instigate
d mass vaccination after a sustained increase in serogronp C meningococcal
disease. Ln the same year, Victoria, Australia experienced a similar change
in disease epidemiology. It is timely to undertake an economic evaluation
of options for community vaccination in Australia based on local data.
Methods Cost-effectiveness and cost-benefit analyses of three options for u
se of polysaccharide vaccine were undertaken for a hypothetical population
aged 15-19 years. Baseline analyses assumed 5 years' duration of vaccine pr
otection following a single year of programme implementation. Sensitivity a
nalyses of key variables were performed, including vaccine coverage and eff
ectiveness, case fatality rate and the discount rate. Outcomes included the
number of people vaccinated, cases averted, life-years saved and disabilit
y-adjusted life-years (DALY) averted. Cost-benefit analysis used lost earni
ngs avoided as a measure of vaccination benefit.
Results Vaccination of people aged 15-19 years in a defined population with
a high rate of disease was the most cost-effective option. Compared with n
o vaccination and assuming 5 years' duration of protection and exclusion of
direct cost savings, this resulted in a discounted cost per life-year save
d of $23 623, a cost per DALY avoided of $21 097 and benefits exceeding cos
ts in discounted terms. The 'break-even' incidence rate for this option wit
h exclusion of direct cost savings was 14.0/100 000.
Conclusions Community use of polysaccharide vaccination may be cost effecti
ve in Australia under certain conditions. Economic evidence favours use of
vaccination in well-defined populations with a high rate of disease. Policy
decision-making also requires consideration of non-economic factors, inclu
ding feasibility of implementation and risk perception by the community.